LLY - Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19

Eli Lilly (LLY) and Incyte (INCY) say the U.S. Food and Drug Administration issued an emergency use authorization for their baricitinib arthritis drug in combination with Gilead Sciences' (GILD) remdesivir to treat hospitalized patients with COVID-19."This is an important milestone for hospitalized patients on oxygen, as baricitinib may help speed their recovery," Eli Lilly Chairman and CEO David Ricks says.In a clinical trial of hospitalized patients with COVID-19, a combination of baricitinib and remdesivir was shown to reduce time to recovery to within 29 days after starting treatment compared to patients who received a placebo with remdesivir.

For further details see:

Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19